Cidara TherapeuticsCDTX
CDTX
About: Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
Employees: 73
0
Funds holding %
of 7,431 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
775% more first-time investments, than exits
New positions opened: 70 | Existing positions closed: 8
512% more capital invested
Capital invested by funds: $206M [Q1] → $1.26B (+$1.05B) [Q2]
480% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 5
200% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 9 (+6) [Q2]
133% more funds holding
Funds holding: 46 [Q1] → 107 (+61) [Q2]
33.8% more ownership
Funds ownership: 87.3% [Q1] → 121.1% (+33.8%) [Q2]
51% less call options, than puts
Call options by funds: $35.4M | Put options by funds: $72.6M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$45
32%
downside
Avg. target
$65
1%
downside
High target
$75
14%
upside
7 analyst ratings
7 positive
100%
0 neutral
0%
0 negative
0%
JMP Securities Roy Buchanan | 0%upside $66 | Market Outperform Maintained | 8 Aug 2025 |
Needham Joseph Stringer | 13%upside $74 | Buy Maintained | 8 Aug 2025 |
HC Wainwright & Co. Sara Nik | 13%upside $74 | Buy Maintained | 8 Aug 2025 |
RBC Capital Brian Abrahams | 14%upside $75 | Outperform Maintained | 24 Jun 2025 |
Guggenheim Seamus Fernandez | 3%upside $68 | Buy Maintained | 24 Jun 2025 |
Financial journalist opinion
Based on 4 articles about CDTX published over the past 30 days
Positive
Seeking Alpha
1 week ago
Cidara Therapeutics: Still Big Catalysts Ahead Following Impressive Ph2b Readout
Cidara Therapeutics, Inc.'s CD388's strong phase 2b results significantly de-risk CDTX and highlight its potential as a superior flu prophylactic, especially for high-risk patients. Multiple short-term catalysts—including FDA meeting, BARDA funding, potential early start of phase 3 and breakthrough designation—could accelerate development and drive further upside. Cidara is well-funded through phase 3, with $516.9M in cash, and is an attractive acquisition candidate after its impressive trial results.
Neutral
Seeking Alpha
2 weeks ago
Cidara Therapeutics, Inc. (CDTX) Q2 2025 Earnings Call Transcript
Cidara Therapeutics, Inc. (NASDAQ:CDTX ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Frank L. Karbe - Chief Financial Officer Jeffrey L.
Positive
The Motley Fool
2 weeks ago
Cidara (CDTX) Q2 Cash Surges 163%
Cidara (CDTX) Q2 Cash Surges 163%
Neutral
GlobeNewsWire
2 weeks ago
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Phase 2b NAVIGATE clinical trial evaluating CD388 for the prevention of seasonal influenza met primary and all secondary efficacy endpoints for all dose groups End of Phase 2 meeting request submitted to the U.S. Food and Drug Administration (FDA) Closed upsized public offering for gross proceeds of $402.5 million; significantly strengthened balance sheet to conduct planned Phase 3 program for CD388 Added to Russell 2000 ® and Russell 3000 ® Indexes Conference call and webcast today at 5:00 PM Eastern Time SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company or Cidara), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today reported financial results for the second quarter ended June 30, 2025, and provided recent business updates. “The highly compelling results of our Phase 2b NAVIGATE trial for CD388 and subsequent financing puts us in a position of strength to execute on our Phase 3 plan to examine the potential of CD388, a non-vaccine solution, to provide single-dose per season, universal protection against influenza in individuals at greatest risk from influenza,” said Jeffrey Stein, Ph.D.
Neutral
GlobeNewsWire
1 month ago
Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025
SAN DIEGO, July 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its second quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, August 7, 2025. The Company will host a conference call and webcast at 5:00 PM Eastern Time to discuss the results and provide an update on business operations.
Neutral
Business Wire
1 month ago
Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics
MIAMI LAKES, Fla.--(BUSINESS WIRE)-- #AntiviralTreatment--Segal Trials proudly announces its participation in the successful Phase 2b NAVIGATE clinical trial conducted by Cidara Therapeutics, evaluating CD388—a novel, non-vaccine, long-acting antiviral—for the prevention of seasonal influenza. Dr. Steven Chavoustie served as the Principal Investigator for the study at Segal Trials. The NAVIGATE trial enrolled over 5,000 healthy, unvaccinated adults and met both its primary and secondary efficacy endpoints, showing t.
Neutral
GlobeNewsWire
1 month ago
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the Compensation and Human Capital Committee of its Board of Directors (Compensation Committee) granted non-qualified stock option awards and restricted stock units (RSUs) for an aggregate of 12,100 shares of its common stock to two new employees, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, as amended (the Inducement Plan), with a grant date of June 30, 2025. The stock option has an exercise price of $48.71 per share, which is equal to the closing price of Cidara's common stock on the grant date. The shares subject to the option will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. All RSUs vest in four equal annual installments, with 1/4 vesting on each of the first, second, third and fourth anniversaries of the Quarterly Vesting Date (as defined below) that occurs during the calendar quarter that includes the date of grant. “Quarterly Vesting Date” means March 10, June 10, September 10 or December 10. The awards are subject to the award holder's continuous service through each vesting date and to the terms and conditions of the Inducement Plan and the standard forms of grant agreements thereunder.
Positive
MarketBeat
1 month ago
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
The biopharmaceuticals space is notorious for sudden, sharp rallies, and for precipitous sell-offs as well. The industry is crowded with names, many of which are tiny firms working toward developing a small number of drug candidates and lacking a means of achieving profitability until one or more of those products make it to market.
Neutral
GlobeNewsWire
1 month ago
Cidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its addition to the Russell 2000 ® and Russell 3000 ® Indexes.
Neutral
GlobeNewsWire
2 months ago
Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the closing of its underwritten public offering of 9,147,727 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,193,181 shares, at a price to the public of $44.00 per share. The gross proceeds to Cidara from the offering, before deducting underwriting discounts and commissions and offering expenses, were $402.5 million. All of the shares in the offering were sold by Cidara.
Charts implemented using Lightweight Charts™